No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Newton™ Soft Tissue Management Technology: 1st Surgeries Reported

Editor: What To Know

  • Newton is a sophisticated technology that is designed to provide real-time, patient-specific insights to help easily optimize the soft tissue with the goal of achieving the best possible outcomes for total knee patients.
  • By capturing active balance data through the entire arc of motion with the patella in place, Newton seamlessly integrates with ExactechGPS's connected platform to allow surgeons to visualize a predictive plan through operative insights, without the need for external soft tissue tensioners.
  • Newton™, is an innovative soft tissue management technology that combines dynamic ligament balancing and real-time guidance to bring to life a personalized intraoperative solution designed to improve total knee replacement surgery outcomes and patient satisfaction.

Newton™, is an innovative soft tissue management technology that combines dynamic ligament balancing and real-time guidance to bring to life a personalized intraoperative solution designed to improve total knee replacement surgery outcomes and patient satisfaction.

First Surgeries

First surgeries were performed by Hari K. Parvataneni, MD, professor of orthopaedic surgery at the University of Florida, and James Huddleston III, MD, professor of orthopaedic surgery and chief of the adult reconstruction service at Stanford University Medical Center. According to Huddleston, “Soft tissue management is an area of opportunity for progression in orthopaedics, and Exactech is leading the way. Newton is a sophisticated technology that is designed to provide real-time, patient-specific insights to help easily optimize the soft tissue with the goal of achieving the best possible outcomes for total knee patients.”

What is Newston?

Newton is an innovative intra-articular device that engages the patient’s soft tissue to help surgeons execute a personalized, well-balanced total knee replacement. By capturing active balance data through the entire arc of motion with the patella in place, Newton seamlessly integrates with ExactechGPS’s connected platform to allow surgeons to visualize a predictive plan through operative insights, without the need for external soft tissue tensioners.

Remarks from Exactech Marketing

“We are excited to introduce this game-changing technology for total knee replacement surgery,” said Adam Hayden, Exactech’s chief marketing officer and senior vice president of Large Joints. “Newton is yet another example of Exactech pioneering innovations that provide orthopaedic surgeons with intelligent insights to make smart decisions throughout the journey of care.”

Newton is the company’s latest release within its Active Intelligence platform of smart solutions that help surgeons engage with patients and peers, solve challenges with predictive tools and optimize performance. The technology is in pilot launch in the US with expanded availability planned before the end of the year.

Surgeons can experience Newton and ExactechGPS first-hand at the AAOS Annual Meeting – Booth #1035 – Sept. 1 – 3, 2021, through live demonstrations.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy